Proactive Investors - Run By Investors For Investors

Cosmos posts 3Q profit and strong profit margins on booming drug sales and bolstered balance sheet

CEO Grigorios Siokas is bullish on Cosmos’s outlook and says future acquisitions are next
Earlier this year, Cosmos submitted an application to uplist its stock to NASDAQ

The international pharmaceutical company Cosmos Holdings (OTCQB:COSM) swung to a profit in the third quarter and boosted its profit margins as it strengthened its balance sheet and worked towards its goal of uplisting to the Nasdaq.

For the three months ended September 30, its net profit jumped to $3.2 million, or $0.24 per share, up from a loss of $198,000, or $0.02 per share, for the corresponding period last year. Over the same period, its gross profit margin also rose to 9.3% from 8.1% for the year-ago period.

Operating revenues came to $29.3 million for the nine months ended September 30, up from $19.8 million for the same period last year.

The company also kept a lid on its costs, with its total operating expenses falling to $2.3 million for the nine months ended September 30, from $4.4 million for the same period last year.

In a statement, CEO Grigorios Siokas was bullish on Cosmos’s outlook and said future acquisitions were next.

BIG PICTURE: Cosmos Holdings focuses on Europe as it expands its global wholesale pharmaceutical business

“We maintain our strong focus on organic growth and strategic acquisitions, starting with the pending closing of Cosmofarm LLC and continuing to look towards acquisition targets in Central Europe and North America,” Siokas said.

“I am delighted to announce that the company delivered record quarterly net profit and increased gross profit margins. In addition, during this quarter, the company has strengthened its balance sheet and improved stockholders’ equity. We continue to work towards uplisting onto a national securities exchange,” he added.

Last June, Cosmos raised its profile by formally submitting an application to uplist its common stock to the Nasdaq Composite stock exchange from the OTCQB Venture market.

The move underlines the strides Cosmos has made in strengthening its corporate governance and positioning itself for growth and profitability.

READ: Cosmos Holdings applies to list on the Nasdaq

Cosmos is an international pharmaceutical company with offices and distribution centers in Thessaloniki, Greece and in Harlow in the United Kingdom.

Cosmos shares closed up 13.4% to hit $4.99 on Tuesday.

Contact Ellen Kelleher at [email protected]

View full COSM profile View Profile

Cosmos Holdings Inc Timeline

July 02 2018

Related Articles

A double helix and a medical person
March 06 2019
Leronlimab, according to the company, is an antiviral agent candidate with fewer side effects, lower toxicity and less frequent doses than daily HIV therapies now in use
scientist in lab
December 20 2018
Data from Midatech's MTD201 drug has validated the company's Q-Sphera sustained release technology, and other, bigger players are starting to sit up and take note
Vial of pills
June 25 2018
Cosmos is a modern company, but the trade routes it relies on are ancient
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use